<DOC>
	<DOC>NCT02808026</DOC>
	<brief_summary>To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).</brief_summary>
	<brief_title>Study of CS-3150 in Patients With Severe Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Male and female subjects aged 20 to 80 years at informed consent Subjects with severe hypertension, who do not receive any antihypertensive drugs or receive antihypertensive drug (except for potassiumsparing diuretics) during runin period (Sitting SBP ≥ 180 mmHg or Sitting DBP ≥ 110 mmHg) Patients who are suspected hypertensive emergency Secondary hypertension or malignant hypertension Diabetes mellitus with albuminuria Serum potassium level &lt; 3.5 or ≥ 5.1 mEq/L (≥ 4.8 mEq/L if receive RA inhibitor) eGFR &lt; 60 mL/min/1.73 m^2.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>severe hypertension</keyword>
	<keyword>grade III hypertension</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
</DOC>